Terumo: Notice Regarding the Acquisition of CaridianBCT

March 7, 2011 -- Terumo Corporation (Head Office: Shibuya-ku, Tokyo; President: Yutaro Shintaku - hereinafter "Terumo") today announced that it has entered into a Stock Purchase Agreement to acquire all outstanding shares (the "Acquisition") of CaridianBCT Holding Corp. (Head Office: Colorado, the United States - hereinafter "CaridianBCT"), a leading global provider in the blood transfusion industry as follows:

Ever since it made its first entry into the blood transfusion market in the 1960s, Terumo has been expanding both domestically and internationally, especially in blood bag products, and now has grown into the No.5 blood transfusion player globally. The blood transfusion industry, which showed only modest growth in the past, is now transforming into a dynamic high-growth business segment

There is rising global demand for blood transfusion products, in part due to the aging of the population in developed nations (and increased need for treatments requiring blood products) and, in emerging economies, it is the rapid development of healthcare infrastructure.

In this fast-changing environment, Terumo is focused on expanding its blood transfusion business, as part of its core strategy to achieve the long-term objective of "target revenue of 1 trillion yen within 10 years." The acquisition of CaridianBCT will transform Terumo's transfusion business by expanding Terumo's offerings into complementary business lines and geographies. CaridianBCT is one of the world's leading providers in blood processing technologies for blood banks, hospitals, biotech and therapeutic applications. This transaction will allow Terumo to offer a wider range of blood processing technologies and greatly expand Terumo's geographic presence, particularly in the key North American market.

With this Acquisition, it is possible for Terumo to dramatically drive its growth strategies to achieve the target revenue of 1 trillion yen.